Constantly seek and gather knowledge

Appointed Director of the Scientific Committee at  Fojann Biopharmaceuticals limited - assuming this or similar as official name] in February 2025.

Holds a Ph.D. in Pathology from McGill University, Canada, and completed postdoctoral research at Harvard Medical School, USA. Starting in 1994, served as a New Drug Reviewer at the U.S. FDA for 7 years. After leaving the FDA at the end of 2000, successively held positions as Director of Regulatory Affairs at United Healthcare, USA, and Senior Director of Clinical and Regulatory Affairs at Hutchison Whampoa Medicines, Hong Kong. Subsequently, served as CEO and Chief Pharmaceutical Development Consultant at Humphries Pharma Consulting Co., Ltd., where he led new drug development teams from diverse countries, cultural backgrounds, and professional expertise, successfully completing the development and submission of over 100 new drugs. Currently serves as a Visiting Professor at Peking Union Medical College, President of the FDA Expert Society, Chairman of the Tongxieyi Elite Club, and the incoming Chairman of the International Regulatory Affairs Committee of a Pharmaceutical Association.